Essential Clinical Data
Uroplasty's commitment to provide customers with safe and effective products is backed by extensive clinical data.
Urgent® PC Neuromodulation System
For overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence
Office-based neuromodulation, delivered through Percutaneous Tibial Nerve Stimulation (PTNS), has been the subject of 30+ clinical publications. Up to 80% of patients respond to PTNS treatment and see significant improvements in their symptoms. Side-effects associated with the treatment are minimal and minor. The Urgent PC Neuromodulation System is the only FDA-cleared system available to provide PTNS treatment.
Macroplastique® Injectable Bulking Agent
For adult female stress urinary incontinence
Macroplastique has been used in Europe since 1991 with excellent clinical results. The FDA premarket approval study reinforced exceptional performance of Macroplastique as compared to the control, a currently marketed absorbable bulking agent. There were no serious treatment-related adverse events noted in the Macroplastique group; rate and type of adverse events was similar to the Control group.
> See Macroplastique Clinical Data
0540052B 2/11
MORE CLINICAL DATA
